We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

39 hedge funds and large institutions have $82.7M invested in Inozyme Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.87% less ownership

Funds ownership: 78.68% → 76.81% (-1.9%)

17% less funds holding

Funds holding: 47 → 39 (-8)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

45% less capital invested

Capital invested by funds: $149M → $82.7M (-$66.7M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

Holders
39
Holders Change
-8
Holders Change %
-17.02%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
2
Increased
11
Reduced
15
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
+$606K
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$181K
3
BCM
Bridgeway Capital Management
Texas
+$166K
4
Renaissance Technologies
Renaissance Technologies
New York
+$134K
5
State Street
State Street
Massachusetts
+$98.8K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$2.19M
2
Janus Henderson Group
Janus Henderson Group
-$812K
3
BBA
Baker Bros. Advisors
New York
-$510K
4
CA
CHI Advisors
New York
-$136K
5
E
Ergoteles
New York
-$122K

INZY Hedge Fund Activity: Q3 2022 in Review

39 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2022, worth a combined $82.7M — down 45% from $149M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of INZY and 2 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 11 added.

The largest buyer was Rock Springs Capital Management, adding an estimated $606K. The largest seller was Deerfield Management, cutting an estimated $2.19M.

  • 39 institutional investors held Inozyme Pharma (INZY) as of Q3 2022, down from 47 in Q2 2022.
  • Funds reported $82.7M of Inozyme Pharma stock for Q3 2022, down 45% quarter-over-quarter.
  • 2 funds opened new Inozyme Pharma positions in Q3 2022 and 10 closed out, a net change of -8 holders.
  • The largest Inozyme Pharma buyer in Q3 2022 was Rock Springs Capital Management, an estimated $606K added.
  • The largest Inozyme Pharma seller in Q3 2022 was Deerfield Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q3 2022.